Literature DB >> 1984688

Effective therapy of human immunodeficiency virus-associated anemia with recombinant human erythropoietin despite high endogenous erythropoietin.

N A DaCosta1, M B Hultin.   

Abstract

A 32-year-old woman with human immunodeficiency virus (HIV) infection and progressive anemia presented to University Hospital with a hemoglobin of 3.4 g/dl. Because of her religious beliefs, she refused transfusion, and no iron or vitamin deficiency was found. She responded to recombinant human erythropoietin 150 U/kg intramuscularly thrice weekly with a rise in hemoglobin to 9.3 g/dl by 3 months of treatment. The serum erythropoietin level before treatment was markedly elevated at 1,340 mU/ml.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984688     DOI: 10.1002/ajh.2830360118

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  1 in total

1.  Effect of recombinant human erythropoietin after allogenic bone marrow transplantation.

Authors:  H Link; T Brune; G Hübner; H Diedrich; M Freund; M Stoll; D Peest; W Ebell; C Bettoni; W Oster
Journal:  Ann Hematol       Date:  1993-10       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.